Do you have systemic sclerosis and experience painful Raynaud’s phenomenon attacks?

You may be eligible for the Aurora study!
This clinical study will look at whether the study drug therapy can lower the frequency and severity of symptomatic Raynaud’s phenomenon (RP) attacks in people with systemic sclerosis (SSc).

You must meet other criteria to qualify.

Eligible participants will receive:
- Potential access to the study drug therapy
- Study-related health assessments and follow-up provided by a healthcare team
- Education about systemic sclerosis (SSc) and symptomatic Raynaud’s phenomenon (RP)
- Travel support

To learn more about the Aurora study, contact:
University of Arizona Arthritis Center
ArthritisResearch@arthritis.arizona.edu
520-626-8379